Dopamine Agonists has 23 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Esmolol Hydrochloride, Hyaluronidase, Hyaluronidase, Ovine. Patients taking Dopamine Agonists should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 23
- Contraindicated
- 3
- Major
- 3
- Moderate
- 17
Contraindicated (3)
- Dopamine Agonists + Esmolol Hydrochloride— Do not use esmolol to control tachycardia in patients receiving dopamine due to risk of reducing cardiac contractility i…
- Dopamine Agonists + Hyaluronidase— Hyaluronidase should not be used to enhance the dispersion and absorption of dopamine.
- Dopamine Agonists + Hyaluronidase, Ovine— Hyaluronidase should not be used to enhance absorption and dispersion of dopamine.
Major (3)
- Dopamine Agonists + Carbidopa, Levodopa And Entacapone— May result in increased heart rates, possibly arrhythmias, and excessive changes in blood pressure. Metabolized by COMT.
- Dopamine Agonists + Deutetrabenazine— Concomitant use may increase risk of parkinsonism, neuroleptic malignant syndrome, and akathisia.
- Dopamine Agonists + Olanzapine And Samidorphan L-Malate— Concomitant use is not recommended due to dopamine antagonism by olanzapine potentially reducing agonist efficacy.
Moderate (17)
- Dopamine Agonists + Atomoxetine— Pressor agent that may cause effects on blood pressure when used with atomoxetine; use with caution.
- Dopamine Agonists + Atomoxetine Hydrochloride— Pressor agent; possible effects on blood pressure when used with atomoxetine.
- Dopamine Agonists + Fluorodopa F18— May interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.
- Dopamine Agonists + Haloperidol Decanoate— Haloperidol may antagonize the effects of dopamine agonists and other drugs intended to increase dopamine levels.
- Dopamine Agonists + Haloperidol Lactate— Haloperidol may impair antiparkinson effects of dopamine agonists; extrapyramidal symptoms may occur if both are discont…
- Dopamine Agonists + Histamine Phosphate— Intravenous infusion of dopamine inhibits skin test responses to histamine.
- Dopamine Agonists + Levothyroxine Sodium— May reduce TSH secretion transiently at doses ≥1 mcg/kg/min when levothyroxine is used.
- Dopamine Agonists + Olanzapine— Olanzapine may antagonize dopamine agonists.
- Dopamine Agonists + Olanzapine And Fuoxetine— Olanzapine and fluoxetine may antagonize dopamine agonist effects.
- Dopamine Agonists + Paliperidone— Paliperidone may antagonize the effect of dopamine agonists; use with caution.
- Dopamine Agonists + Paliperidone Palmitate— Paliperidone may antagonize the effects of dopamine agonists. Monitor and manage patient as clinically appropriate.
- Dopamine Agonists + Quetiapine— Quetiapine may antagonize the effects of dopamine agonists. Caution advised with concomitant use.
- Dopamine Agonists + Quetiapine Fumarate— Quetiapine may antagonize the effects of dopamine agonists.
- Dopamine Agonists + Risperidone— Risperidone may antagonize the effects of dopamine agonists.
- Dopamine Agonists + Ziprasidone— Ziprasidone may antagonize the effects of dopamine agonists.
- Dopamine Agonists + Ziprasidone Hcl— Ziprasidone may antagonize the effects of dopamine agonists, potentially reducing their therapeutic efficacy.
- Dopamine Agonists + Ziprasidone Mesylate— Ziprasidone may antagonize the effects of dopamine agonists.